CMO Formulation Market Intelligence


With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


 No Additional Benefits

Subscription Benefits:

  • PRO access to New Beroe LiVE*
  • Unlimited updates on the Report*
  • Supplier Watchlist for 3 suppliers*
  • Supplier Shortlisting Tool*

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


*These features will be unlocked on the new Beroe LiVE when it launches (Q3, 2020)

Are you looking for answers on CMO Formulation category?

Are you looking for answers on CMO Formulation category?

  • What are the key trends in CMO Formulation category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in CMO Formulation industry?
  • How is CMO Formulation industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Global Capacity–Demand Analysis
  • Global Trade Dynamics
  • Regional Market Snapshot-North America, Europe, Asia
  • Cost Structure Analysis

Market Size

Market Size Europe

$16.4 Bn

Market Size Latin America

$1.75 Bn

Market Size US

$27.3 Bn

Market Size China

$6 Bn

Table of contents

  1. CMO Formulation Executive Summary
  2. Global CMO Industry Outlook
  3. Regional Market Outlook
  4. Supplier Landscape and Export Capability
  1. CMO Formulation Market Analysis
  2. Category Overview - Products within Category
  3. Global CMO Formulations - Market Overview
  4. Global CMO Market - Drivers and Constraints
  5. Growth Correlation - Global Pharmaceutical Market vs. Global CMO Market
  6. Global CMO Formulation Overview
  7. Regional Market Outlook
  1. CMO Formulation Industry Analysis
  2. Day One Analysis
  3. Category Portfolio Analysis
  5. Porter’s Five Forces Analysis
  6. SWOT Analysis
  7. Key Industry Trends and Market Shifts
  8. Emerging Trends
  9. Emerging Market Sourcing - Cost- Saving Initiative
  1. CMO Formulation Competitive Landscape
  2. Big Pharma and CMO Partnerships in USA
  3. Europe
  4. Japan
  5. China
  6. India
  1. CMO Formulation Supply Analysis
  2. Key Regional Suppliers: Service Portfolio
  3. Key Global Supplier Profiles
  4. Major Capacity Expansions
  5. Major Partnerships
  6. Mergers & Acquisitions
  7. Technology Trends and Case Study
  8. Regulatory Developments in CMO Space
  1. CMO Formulation Procurement Best Practices
  2. Big Pharma’s Preferred Business Models
  3. Big Pharma - Generic Outsourcing
  4. Generic Pharma - Emerging Market Sourcing
  5. CMO Mark-up & Cost Structure

Want a more detailed personalised report?

Global Market Outlook on CMO Formulation

  • The global CMO Market is growing at a CAGR of 12–13 percent CAGR between 2018E and 2022 E
  • The growth is attributed to increased outsourcing of generic drugs by Big Pharma companies. Additionally, medium and small pharma companies, who do not possess adequate infrastructure, will also outsource, thereby driving the market
  • Presently, non-sterile dominate the global CMO market. However, the sterile CMO market is expected to grow at a higher rate (15 percent) than non-sterile market (9 percent)


Global CMO Formulations: Market Overview

Supplier Concentration: Sterile CMOs
The CMO sterile market is fragmented, with major players, such as Baxter, Catalent, Patheon, etc. However, CMOs differentiate their capabilities, based on their ability to handle the high potent drugs (OEL limit).Supplier

Concentration - Non-Sterile CMOs
Fragmented market, with a large number of players and varying ranges of capacity, capabilities, and regulatory compliances. Asian CMOs are offering competitive cost benefits, thus giving a stiff competition to CMOs in developed markets.

Global CMO Formulations Market - Drivers and Constraints


  • The pharmaceutical sector's tendency to focus on core competencies and a trend to outsource formulations to CMOs to achieve cost savings are the major market drivers.
  • Requirement for end-to-end service providers, including drug development and manufacturing, is further driving the CMO market.
  • In emerging markets, countries, such as Russia, Ukraine, Indonesia, and Iran, are promoting domestic production of drugs, which is expected to boost the outsourcing to regional CMOs


  • As the market is highly fragmented, margins of traditional CMOs, who offer conventional manufacturing services, are under pressure.
  • Introduction of GDUFA is expected to have a negative impact on CMOs' profits. In such cases, small CMOs are expected to transfer the incremental cost to their customers, which would affect their business.
  • CMOs predominantly manufacture generic drugs. The volume of generic drugs decreases annually, leading to a constant look out for business to maintain their utilization rates

Key Industry Trends and Market Shifts

  • Currently, in the developed market, solid dosage dominates the outsourced market
  • Over the next five years, the sterile CMO market is expected to grow at a higher pace
  • In the US, the sterile CMO market is expected to grow at 11–13 percent as against the solid dosage growth of 3–5 percent
  • Emerging market CMOs would offer stiff competetion to develped market CMOs in solid dosages

CMO Market Overview 

  • The global CMO market is fragmented. To sustain in the market with high-profit margins and to compete with each other, CMOs have started innovating technologies across dosage forms. OptiMelt, SmartTag, AdvaSept, Nanomiling, etc., are examples.
  • Formulation CMO proprietary technologies have made the pharma companies to shift to CDMO partnerships.
  • Existing utilization rates among CMOs globally assures adequate number of CMOs.
  • Increase in pharma outsourcing from 17–20 percent to 28–30 percent by 2018.
  • Upgradation of facilities by CMOs in aseptic filling, lyophilization, and disposable technologies.
  • The global CMO market for finished dosage sterile formulations is highly capital intensive.
  • The CMO market for finished dosage formulations in established (developed) markets is fragmented, with many players having similar processing and technological capabilities.
  • CMOs are transitioning their relationship from being a manufacturing partner to a strategic partner by offering end-to-end service. 
  • Due to the fragmented nature, CMOs are under pricing pressure. Though the revenue of CMOs has increased in the last two years, their profit margins have been stagnant.
  • There is a fragmented market for finished dosage formulation CMO. In order to sustain in the market, the CMOs have to continuously evolve with innovative technologies and best manufacturing practices.
  • Most of these finished dosage formulation CMO source excipients from emerging economies, like BRIC nations and APAC, which are dominated by a large number of suppliers. In case of patented excipients sourcing, supplier will have a higher bargaining power

Why You Should Buy This Report

  • Information about the global CMO market size, market overview, drivers and constraints, etc.
  • Regional market outlook of formulation CMO in US, China, India, and Europe.
  • Day one analysis, category portfolio analysis, AQSCIR, SWOT analysis of the global CMO market and Porter’s five force analysis of CMO sterile and non-sterile formulations.
  • Emerging CMO trends,  supplier analysis, key supplier profiles, etc.
  • Best procurement practices, cost structure, sourcing, etc.

With this purchase you will be subscribed for a 12-month PRO membership to the upcoming all new Beroe LiVE (launching in Q3, 2020)


Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.


COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)